James Moren

Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis

Systematic review or meta-analysis · Expert Review of Pharmacoeconomics & Outcomes Research · 2022 · Last of 10 authors · 21 citations

Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the…

Headache · 2021 · Last of 9 authors · 16 citations